France’s New Guidelines on Weight Loss Medications: A Turning Point for General Practitioners
In the sphere of weight management, recent developments in France are generating significant interest among healthcare professionals and patients alike. Historically, only renewals of prescriptions were possible for specific weight loss treatments. However, this is now poised to change as the French government moves towards allowing general practitioners (GPs) to prescribe certain anti-obesity medications.
Since their introduction to the market in 2024, two significant treatments have been tightly regulated. Currently, only specialists in endocrinology, diabetology, or nutrition are authorized to prescribe them. This restrictive approach stems from concerns over misuse for cosmetic purposes, given these medications’ proven effectiveness in weight loss.
The Agence nationale du médicament (ANSM) is set to initiate procedures that would allow GPs to prescribe these medications. This decision aligns with requests from Catherine Vautrin, the Minister of Health, and Yannick Neuder, the Minister Delegate for Health and Access to Care. As noted by Anne-Sophie Joly, the president of the national collective of obesity associations, this news is promising: "It’s a good development… these are medications that have been extensively awaited." She highlights the urgency of the situation, emphasizing that "ten million people suffer from obesity. If you add all those with overweight, it reaches half of the French population."
Understanding the Medications: Wegovy and Mounjaro
The medications in question are Wegovy® and Mounjaro®, produced respectively by Danish pharmaceutical giant Novo Nordisk and American pharmaceutical company Eli Lilly.
Wegovy® contains semaglutide, a hormone that regulates satiety, effectively helping individuals manage their hunger. In contrast, Mounjaro® combines tirzepatide, which has demonstrated significant effects on weight loss. Both medications are analogs of GLP-1, similar to the well-known Ozempic®, and are administered via injection in the abdominal area. They are intended for individuals struggling with overweight, obesity (defined as having a Body Mass Index of over 35), and type 2 diabetes.
Challenges Ahead: Cost and Access
As these medications gain potential approval for general practitioners, challenges still loom. Currently, the cost of Wegovy® is extraordinarily high, priced at approximately 300 euros per box. Additionally, these medications are not covered by France’s health insurance, making them financially inaccessible for many.
Yannick Neuder has acknowledged the pressing need for feedback, stating that the ANSM will conduct a "phase of inquiry among prescribers to gather best practices." This process aims to enrich data collection and share successful treatment strategies.
It is crucial to note that while the prospect of broader access to these medications is promising, they come with responsibilities. Medical professionals will need to intelligently assess patient profiles, ensuring that these treatments are used safely and appropriately.
The Impact on Public Health
The potential expansion of prescription rights to GPs represents a significant shift in France’s public health approach. With obesity and overweight being critical health concerns, allowing general practitioners more autonomy to prescribe these medications might provide timely interventions for countless individuals.
Anne-Sophie Joly reinforced the collective responsibility of healthcare providers: "We need to ensure that these treatments are deployed fairly and effectively." This statement underscores the pressing nature of the discussion around obesity treatment, as many questions remain.
As the government prepares to act, we can expect a robust debate to ensue regarding guidelines, regulations, and best practices for administering these powerful medications.
The involvement of general practitioners could serve to democratize access to treatments that have historically been available mainly through specialized care, thereby potentially reducing the stigma associated with seeking help for weight-related issues.
Looking ahead, it is essential for healthcare providers, policymakers, and patients to work collectively to navigate this evolving landscape. Success requires the integration of medical research, ethical considerations, economic factors, and, most importantly, the experiences of individuals affected by obesity.
Jusqu’ici, seuls les renouvellements d’ordonnance étaient possibles.
En France, deux traitements font l’objet d’un encadrement strict. Depuis leur arrivée sur le marché en 2024, seuls les spécialistes en endocrinologie, diabétologie ou nutrition peuvent les prescrire. La raison ? Des détournements à des fins esthétiques, liés à leur efficacité prouvée sur la perte de poids. Mais cela pourrait changer.
L’Agence nationale du médicament (ANSM) doit lancer une procédure pour permettre aux médecins généralistes de les prescrire, conformément à la demande faite par Catherine Vautrin, ministre de la santé, et Yannick Neuder, ministre chargé de la Santé et de l’Accès aux soins. “C’est une bonne nouvelle (…) ce sont des médicaments excessivement attendus” a réagi Anne-Sophie Joly, présidente du collectif national des associations d’obèses, auprès de nos confrères de franceinfo. Avant de rappeler que “dix millions de personnes souffrent d’obésité. Si vous ajoutez à cela toutes les personnes qui souffrent de surpoids, on arrive à la moitié de la population française.”
Les deux médicaments sont le Wegovy©, fabriqué par le laboratoire danois Novo Nordisk, et le Mounjaro©, produit par le groupe pharmaceutique américain Eli Lilly. Le Wegovy© contient du sémaglutide, une des hormones qui gère la satiété. Quant au Mounjaro©, il contient du tirzépatide, qui a démontré des effets très significatifs sur la perte de poids. Ces deux médicaments sont des analogues du GLP-1 comme le célèbre Ozempic®. Ils sont administrés sous la forme d’une injection dans le ventre, dans la prise en charge du surpoids, de l’obésité (IMC supérieur à 35) et du diabète de type 2.
L’Agence du médicament doit mener “une phase d’interrogation des prescripteurs pour pouvoir faire remonter les bonnes pratiques“. “Nous sommes dans un recueil de données, mais nous souhaitons avancer sur ce sujet, et si possible avant l’été” a partagé Yannick Neuder. A noter que ces médicaments coûtent cher (300 euros la boîte pour le Wegovy®) et qu’ils ne sont pas remboursés par l’Assurance maladie.